TO Pharma's medicines are rooted in Tikun Olam's 20+ years of experience developing and testing exclusive, proprietary, medical cannibis strains. To date, more than 20,000 patients have been treated with Tikun Olam's strains across a number of medical conditions.
TO Pharma is developing next-generation cannabinoid therapies for debilitating diseases.
Our proprietary hydrogel technology enables the creation of unique over-the-counter cannabidoil (CBD) applications.
Our pharmaceutical medicines are currently being studied in the clinic for pediatric Crohn's disease, Alzheimer's agitation, ulcerative colitis, and other indications.
20+ Years of Experience
The human endocannabinoid system is involved in most major immune events. We're developing medicines beneficial in inflammatory disorders.
Hydrogel technology can be used to deliver CBD to treat a number of conditions.
We have deep experience starting and leading bio-pharmaceutical companies.
Information for investors.